Autolus Therapeutics plc ADR (NASDAQ:AUTL) price on Wednesday, April 30, rose 7.63% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $1.41.
A look at the stock’s price movement, the close in the last trading session was $1.31, moving within a range at $1.27 and $1.41. The beta value (5-Year monthly) was 2.06. Turning to its 52-week performance, $5.00 and $1.11 were the 52-week high and 52-week low respectively. Overall, AUTL moved -9.03% over the past month.
Autolus Therapeutics plc ADR’s market cap currently stands at around $375.23 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Mar-19.
The average forecast suggests down to a -80.39% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 35.55M, representing a 251.28% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that AUTL is a 50% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
3 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 3 recommend AUTL as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
AUTL’s current price about 2.47% and -13.90% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 46.93, while 7-day volatility ratio is 10.59% and 12.43% in the 30-day chart. Further, Autolus Therapeutics plc ADR (AUTL) has a beta value of 1.77, and an average true range (ATR) of 0.15. Analysts have given the company’s stock an average 52-week price target of $7.6, forecast between a low of $7.6 and high of $7.6. Looking at the price targets, the low is -439.01% off current price level while to achieve the yearly target high, price needs to move -439.01%. Nonetheless, investors will most likely welcome a -439.01% jump to $7.6 which is the analysts’ median price.
If we refocus on Autolus Therapeutics plc ADR (NASDAQ:AUTL), historical trading data shows that trading volumes averaged 2.19 over the past 10 days and 1.61 million over the past 3 months. The company’s latest data on shares outstanding shows there are 266.13 million shares.
The 9.70% of Autolus Therapeutics plc ADR’s shares are in the hands of company insiders while institutional holders own 53.94% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 11.45 million on 2025-04-15, giving us a short ratio of 6.19. The data shows that as of 2025-04-15 short interest in Autolus Therapeutics plc ADR (AUTL) stood at 567.00002 of shares outstanding, with shares short rising to 9.13 million registered in 2025-03-14. Current price change has pushed the stock -40.00% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the AUTL stock continues to rise going into the next quarter.
